Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.



Cathepsin (Cat) B is a lysosomal cysteine protease which is strongly overexpressed in cancers and premalignant lesions. Cathepsin B expression correlates with the invasiveness and metastatic capabilities of many tumors. In breast cancer, high expression levels of cathepsin B have been linked to highly aggressive tumors. Cathepsin B is also upregulated in a variety of inflammatory cells (including eosinophils, neutrophils, and macrophages). In the study of cardiovascular disease, expression levels of Cat B may provide an inflammation readout that indicates the potential vulnerability of atherosclerotic plaques.

Cat B™ 680 FASTand Cat B™ 750 FAST are fluorescent imaging agents developed for specific and rapid detection of tumors associated Cat B activity. They allow for the fast, non-invasive in vivo imaging of disease status and progression. They are optically silent upon injection and produce a fluorescent signal only after cleavage by Cathepsin B expressed in inflammatory cells and tumor cells. The agents consist of a pair of quenched fluorophores separated by a highly selective Cat B substrate. Upon cleavage by Cat B, the agent de-quenches and becomes highly fluorescent. In addition, they are conjugated to a pharmacokinetic modifier (PKM), which improves the pharmacokinetic profile. They are members of a family of activatable fluorescent imaging agents comprising this novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology). This architecture offers higher target specific signal with reduced background and an improved pharmacokinetic profile with a broader range of early imaging time points.

Figure 1: Cat B FAST agents are composed of a Cat B-specific peptide flanked by two near-infrared (NIR) fluorochromes and a pharmacokinetic modifier (PKM) selected to provide optimal attributes for in vivo imaging. Upon Cat B cleavage of the substrate sequence the Cat B FAST agents become highly fluorescent.

Figure 2: Cat B 750 FAST (0.5 mM) was cleaved in the presence of 0.05-0.1 mM activated human and mouse cathepsins B, K, L, S and D, legumain and MMPs 2, 9, 12, and 13 at an optimal pH and temperature. The fluorescence was read using a fluorescence microplate reader at 5 hours and 24 hours. Cat B 750 FAST is expected to be preferentially cleaved by Cat B in vivo, based on fast Cat B cleavage and short exposure profile in circulation (< 2 hours).

Products and catalog numbers

ProductCatalog NumberEx/Em wavelength (nm)Molecular weight (g/mol)Validated ExperimentsApplicationsStorage and Stability
Cat B 680 FASTNEV11112675/69333,000In vivo/Ex vivo
Flow cytometry
In vitro microscopy
Neurological diseases
Technical Data Sheet
Cat B 750 FASTNEV11098750/77023,000In vivo/Ex vivo
Flow cytometry
In vitro microscopy
Neurological diseases
Technical Data Sheet

Using Cat B FAST in vivo/ex vivo

  • For Cat B 680 FAST, we recommend intravenous injection and image 6-24 hours post injection. Some applications like imaging of atherosclerotic plaques may require a 4 nmol dose and may benefit from a later imaging time point. 
  • For Cat B 750 FAST, we recommend intravenous injection and imaging 6 hours post injection. Some applications like imaging of atherosclerotic plaques require an 8 nmol dose and may benefit from a later imaging time point.


Cat B FastRoute of InjectionMouse Dose (25 g)Rat Dose (250 g)Blood t 1/2Tissue t 1/2Optimal imaging timeOptimal Re-injection Time (complete clearance)Route of Metabolism/ background tissueFMT and IVIS settings
Cat B 680 FASTIV2 nmol; (4 nmol atherosclerosis)6-20 nmol5 min36 h6-24 h3 dSalivary glands > liver, kidneysFMT 680/700
IVIS 675/720
Cat B 750 FASTIV4 nmol; (8 nmol atherosclerosis)12 nmol5 min36 h6-24 h3 dSalivary glands > liver, kidneysFMT 750/770
IVIS 745/800

In Vivo/Ex Vivo Imaging

Figure 3: HT-29 tumor-bearing mice were injected intravenously with Cat B 750 FAST and imaged by FMT at 2, 4, 6, 24 and 48 hours. Panels show the tomographic images of a representative mouse at each time point. Cat B 750 FAST activation was quantified in pmols and signal was seen in as little as 2 hours. A plateau was reached between 6 and 24 hours which offers a large imaging window. Signal can easily be washed out by 48 hours. In the lower right panel, tumors were excised and snap-frozen after the 6 hours and were visualized by fluorescence microscopy at 40x and 100x magnification. As shown here, Cat B 750 FAST is localized mostly at the tumor periphery but also inside the tumor.

Figure 4: HT-29 colorectal carcinoma cells were subcutaneously injected into the left and right mammary pad in 12 female athymic nu/nu mice. Eight days after implantation, when tumors had reached an average volume of 27 mm3, six animals received 170 mg/kg cyclophosphamide intraperitoneally and 40 mg cyclophosphamide/kg/day in their drinking water. Six remaining animals received no treatment. Tumor volume was monitored for ten days. Mice were then injected intravenously with Cat B 750 FAST in 100 μl of PBS and imaged 6 hours later by FMT imaging. A. This graph shows the tumor growth over a ten day period with and without the cyclophosphamide treatment. B. The quantification of the tumor fluorescence (pmol) shows a significant increase in Cat B 750 FAST signal (72%) with cyclophosphamide treatment despite significantly smaller tumor volumes (46%) relative to control animals. C. Representative volume rendering projections of control and cyclophosphamide treated mice and anti-MAC3 immuno-fluorescent labeling (shown in green) in the ex vivo tumors, indicating increased TAM infiltration in cyclophosphamide treated animals at 40X magnification. DAPI staining is shown in blue.

Ex Vivo Imaging

Figure 5: Cat B 750 FAST was intravenously injected into HT-29 tumor-bearing mice. Organs from these mice were excised at 6 hours after injection and imaged on the FMT 2500 in reflectance mode. A) The 2D planar fluorescence image. B) Mean fluorescence intensity (FLU) of tumors and organs. Cat B 750 FAST activates primarily in tumors with less signal in other organs.


Frozen Tissue Protocol

We have validated Cat B 680 FAST for use with frozen tissue samples (Cat B 750 FAST has not been tested). Here is a brief protocol with a recommended concentration of agent to use:

  1. Freeze tumor/tissue (without agent) and section 5-10 µm by cryostat.
  2. Incubate with 1 µM Cat B 680 FAST at 37ºC for 10 min.
  3. Wash 2x with PBS. 
  4. Mount with anti-fade reagent.
  5. Fluorescence microscopy filter: Cy5.5

Using Cat B FAST in vitro

Cat B 680 FAST and Cat B 750 FAST can be used for detecting and monitoring Cat B activity in tumor and inflammatory cells lines.

Flow cytometry and in vitro microscopy

We have validated Cat B FAST for use with fluorescence microscopes and flow cytometers. Here is a brief protocol with a recommended concentration of agent to use:

  1. Culture cells in standard TC plate or chamber slide. 
  2. Incubate cells with 1 µM Cat B 680 FAST or Cat B 750 FAST for 6-24 hours at 37°C. 
  3. Wash 1x with PBS. For flow cytometry, detach and resuspend cells in PBS. 
  4. Flow cytometry filter settings: 712/21 (Cat B 680 FAST), 780/60 (Cat B 750 FAST)
    Fluorescence micrsocopy filter: Cy 5.5 (Cat B 680 FAST), Cy5.5 or Cy7* (Cat B 750 FAST)

In Vitro Imaging

Figure 6: Raw 264.7 mouse macrophages were incubated with1 μM final concentration of Cat B 750 FAST. Cathepsin inhibitors (50 μM) were added 1 hour before addition of the agent. E64d cell-permeable cysteine/calpain inhibitor and CA-074Me specific cell-permeable cathepsin B inhibitor were used. Cells were then analyzed by fluorescence microscopy. Cat B 750 FAST is activated by RAW macrophages (shored), while the pan-cathepsin inhibitor E64d and the specific cathepsin B inhibitor CA-074Me significantly reduce the activation.


Q. Can I use Cat B FAST agents in humans?

A. No, Cat B FAST agents are intended for animal research only and not for use in humans.

Q. I was wondering if it might be possible to obtain a functionalized version of CAT B 680 fast for covalent attachment to a lipid (e.g. a carboxylic acid)?

A. We don’t currently have any Cat B agents that can attach to a lipid.


Please visit our Citations Library for references using Cat B FAST on the IVIS or on the FMT.